We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Mylan NV | NASDAQ:MYL | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 15.855 | 15.71 | 15.90 | 0 | 01:00:00 |
From Jun 2019 to Jun 2024
The European Commission Wednesday said it has opened an antitrust case against Les Laboratoires Servier and several other drug makers, suspecting they colluded to keep the generic form of a blood pressure medication off the market.
The commission, the European Union's regulatory arm, said Teva Pharmaceutical Industries Ltd. (TEVA), Krka d.d. (KRKG.LJ), Lupin Ltd. (500257.BY), Matrix Laboratories Ltd. (524794.BY), a subsidiary of Mylan Inc. (MYL), and Niche Generics Ltd., a unit of Unichem Laboratories Ltd. (506690.BY) also are involved in its antitrust probe.
The case, which could lead to fines against the companies, follows a broader commission investigation into the pharmaceutical sector. That study identified problems in the way companies that develop drugs compete with generic producers.
Les Laboratoires Servier developed the blood pressure medication perindopril, a so-called ACE inhibitor. The drug is sold under several brand names, including Coversyl and Aceon.
The commission said it suspects Les Laboratoires Servier might have violated antitrust laws, both through its own actions, and in concert with the other drug companies. It didn't disclose details of these possible offenses.
-By Adam Cohen, Dow Jones Newswires; +322 741 1486; adam.cohen@dowjones.com
1 Year Mylan NV Chart |
1 Month Mylan NV Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
